Analysts See $2.06 EPS for Bayer AG (ADR) (BAYRY)

July 17, 2017 - By Adrian Mccoy

 Analysts See $2.06 EPS for Bayer AG (ADR) (BAYRY)

Analysts await Bayer AG (ADR) (OTCMKTS:BAYRY) to report earnings on July, 26. They expect $2.06 earnings per share, down 11.97 % or $0.28 from last year’s $2.34 per share. BAYRY’s profit will be $1.70B for 15.58 P/E if the $2.06 EPS becomes a reality. After $2.80 actual earnings per share reported by Bayer AG (ADR) for the previous quarter, Wall Street now forecasts -26.43 % negative EPS growth. The stock decreased 0.77% or $1 on July 17, reaching $128.37. About 77,620 shares traded or 7.56% up from the average. Bayer AG (ADR) (OTCMKTS:BAYRY) has 0.00% since July 18, 2016 and is . It has underperformed by 16.70% the S&P500.

Bayer AG (ADR) (OTCMKTS:BAYRY) Ratings Coverage

Among 6 analysts covering Bayer AG (OTCMKTS:BAYRY), 4 have Buy rating, 1 Sell and 1 Hold. Therefore 67% are positive. Bayer AG had 8 analyst reports since September 21, 2015 according to SRatingsIntel. The company was upgraded on Thursday, August 25 by Citigroup. The stock of Bayer AG (ADR) (OTCMKTS:BAYRY) has “Hold” rating given on Friday, October 30 by HSBC. The rating was upgraded by HSBC to “Buy” on Thursday, December 10. Jefferies upgraded the stock to “Buy” rating in Monday, December 19 report. The firm has “Neutral” rating given on Wednesday, December 2 by Citigroup. The firm has “Sell” rating given on Monday, September 21 by Zacks. The stock of Bayer AG (ADR) (OTCMKTS:BAYRY) has “Buy” rating given on Wednesday, December 7 by UBS. JP Morgan downgraded the stock to “Neutral” rating in Tuesday, January 5 report.

Bayer AG is a life science company. The Company’s divisions are Pharmaceuticals, Consumer Health, Animal Health and Covestro. The company has market cap of $105.75 billion. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women’s healthcare, and on specialty therapeutics in the areas of oncology, hematology and ophthalmology. It has a 19.8 P/E ratio. The Pharmaceuticals division also comprises the radiology business.

More notable recent Bayer AG (ADR) (OTCMKTS:BAYRY) news were published by: Seekingalpha.com which released: “German Bayer Looks Attractive” on December 22, 2015, also Seekingalpha.com with their article: “Bayer on deck with nine abstracts at ASCO” published on May 18, 2017, Seekingalpha.com published: “Safety Worries Loom For Bayer’s Adempas” on May 13, 2016. More interesting news about Bayer AG (ADR) (OTCMKTS:BAYRY) were released by: Seekingalpha.com and their article: “It’s official: Bayer buys Monsanto for $128/share” published on September 14, 2016 as well as Seekingalpha.com‘s news article titled: “Bayer-Monsanto Merger: Uncertainty Means Buy And Hold” with publication date: September 16, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.